A systematic review of biomarkers for disease progression in alzheimer's disease

PLoS ONE

Volumn 9, Issue 2, 2014, Pages

  McGhee, David J M ^a   Ritchie, Craig W ^b   Thompson, Paul A ^c   Wright, David E ^c   Zajicek, John P ^c   Counsell, Carl E ^a  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF PLYMOUTH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

AGE DISTRIBUTION; ALZHEIMER DISEASE; ANTHROPOMETRIC PARAMETERS; ARTICLE; BRAIN ELECTROPHYSIOLOGY; BRAIN SIZE; BRAIN VENTRICLE SIZE; CEREBROSPINAL FLUID ANALYSIS; DISEASE COURSE; DISEASE DURATION; EMBASE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MEDLINE; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; STUDY DESIGN; SYSTEMATIC REVIEW; METABOLISM;

ALZHEIMER DISEASE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; HUMANS;

EID: 84895888957     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0088854     Document Type: Article

References (29)

1. Knapp M, Prince M, Albanese E, Banjeree S, Dhanasiri S, et al (2007) A report to the Alzheimer's Society on the prevalance and economic cost of dementia in the UK produced by King's College London and the London School of Economics. London: Alzheimer's Society.
2. Knopman DS (2008) Clinical trial design issues in mild to moderate Alzheimer disease. Cogn Behav Neurol 21: 197-201.
3. Knopman D (2006) Finding potent drugs for Alzheimer's disease is more important than proving the drugs are disease modifying. Alzheimers Dement 2: 147-149.
4. Temple RJ (1995) A regulatory authority's opinion about surrogate endpoints. In: Nimmo W, Tucker G, editors. Clinical Measurement in Drug Evaluation. New York: J. Wiley.
5. Biomarkers Definitions Working Group (2001) Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69: 89-95.
6. The Ronald and Nancy Reagan Research Institute of the Alzheimer's Association and the National Institute on Aging Working Group (1998) Consensus report of the Working Group on: "Molecular and Biochemical Markers of Alzheimer's Disease". Neurobiol Aging 19: 109-116.
7. Brooks DJ, Frey KA, Marek KL, Oakes D, Paty D, et al. (2003) Assessment of neuroimaging techniques as biomarkers of the progression of Parkinson's disease. Exp Neurol 184: S68-S79. (Pubitemid 37338706)
8. McGhee DJ, Royle PL, Thompson PA, Wright DE, Zajicek JP, et al. (2013) A systematic review of biomarkers for disease progression in Parkinson's disease. BMC Neurol 13: 35. doi: 10.1186/1471-2377-13-35.
9. McKhann G, Drachman D, Folstein M, Katzman R, Price D, et al. (1984) Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944. (Pubitemid 14076461)
10. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, et al. (2007) Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS-ADRDA criteria. Lancet Neurol 6: 734-746. (Pubitemid 47058377)
11. American Psychiatric Association (1987) Diagnostic and statistical manual of mental disorders: DSM-III-R. Washington DC, USA: American Psychiatric Association.
12. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders. DSM-IV. Washington DC, USA: American Psychiatric Association.
13. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders: DSM-IV-TR. Washington DC, USA: American Psychiatric Association.
14. Mohs RC, Knopman D, Petersen RC, Ferris SH, Ernesto C, et al. (1997) Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 11: S13-S21.
15. Blessed G, Tomlinson BE, Roth M (1968) The association between quantitative measures of dementia and of senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry 114: 797-811.
16. Roth M, Tym E, Mountjoy CQ, Huppert FA, Hendrie H, et al. (1986) CAMDEX. A standardised instrument for the diagnosis of mental disorder in the elderly with special reference to the early detection of dementia. Br J Psychiatry 149: 698-709. (Pubitemid 17205276)
17. Wadsworth LP, Lorius N, Donovan NJ, Locascio JJ, Rentz DM, et al. (2012) Neuropsychiatric Symptoms and Global Functional Impairment along the Alzheimer's Continuum. Dement Geriatr Cogn Disord 34: 96-111.
18. Wolfson C, Moride Y, Perrault A, Momoli F, Demers L, et al. (2000) Drug treatments for Alzheimer's disease. Part 2: A review of outcome measures in clinical trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA).
19. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. Neurobiol Aging 18: S1-S2.
20. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, et al. (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486.
21. Hobart JC, Cano SJ, Zajicek JP, Thompson AJ (2007) Rating scales as outcome measures for clinical trials in neurology: problems, solutions, and recommendations. Lancet Neurol 6: 1094-1105. (Pubitemid 350116704)
22. Kukull WA, Higdon R, Bowen JD, McCormick WC, Teri L, et al. (2002) Dementia and Alzheimer disease incidence: a prospective cohort study. Arch Neurol 59: 1737-1746. (Pubitemid 35340484)
23. Jorm AF, Jolley D (1998) The incidence of dementia: a meta-analysis. Neurology 51: 728-733. (Pubitemid 28449250)
24. Launer LJ, Andersen K, Dewey ME, Letenneur L, Ott A, et al. (1999) Rates and risk factors for dementia and Alzheimer's disease: results from EURODEM pooled analyses. EURODEM Incidence Research Group and Work Groups. European Studies of Dementia. Neurology 52: 78-84. (Pubitemid 29044403)
25. Bewick V, Cheek L, Ball J (2003) Statistics review 7: Correlation and regression. Crit Care 7: 451-459. (Pubitemid 37527231)
26. Brown H, Prescott R (2006) Repeated measures data. In: Applied mixed models in medicine. Chichester: John Wiley & sons. pp.215-270.
27. Alzheimer's Disease Neuroimaging Initiative (ADNI). Available: http://adniinfo.org/. Accessed 2013 Oct 15.
28. Parkinson's Progressive Markers Initiative (PPMI). Available: http://ppmi-info.org/. Accessed 2013 Oct 15.
29. Parkinson's Disease Biomarkers Initiative (PDBP). Available: http://pdbp.ninds.nih.gov/. Accessed 2013 Oct 15.